J. Connelly

发表

Deferiprone‐induced agranulocytosis: 20 years of clinical observations

J. Palmblad, M. Spino, R. Galanello, 2016, American journal of hematology.

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

S. Gillard, M. Spino, F. Tricta, 2013, PharmacoEconomics.

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

S. Gillard, M. Spino, F. Tricta, 2013, PharmacoEconomics.

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial

P. Campochiaro, S. Kaushal, Seng H. Cheng, 2017, The Lancet.

The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.

D. Praticò, M. Spino, A. Lyubarsky, 2011, Investigative ophthalmology & visual science.

Cp/Heph mutant mice have iron‐induced neurodegeneration diminished by deferiprone

J. Connor, P. Krajacic, H. Jinnah, 2015, Journal of neurochemistry.

Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection

M. Mathews, M. Spino, R. Cone, 2013, PloS one.

Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer’s disease

Jiejing Xu, Q. Liu, J. Connelly, 2011, Neuroscience Bulletin.

Action of iron chelator on intramyocardial hemorrhage and cardiac remodeling following acute myocardial infarction

G. Wright, B. Strauss, M. Spino, 2020, Basic Research in Cardiology.

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial

J. Karn, M. Mathews, M. Spino, 2016, PloS one.

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

Maneesh C. Patel, D. Sharp, P. Piccini, 2017, Scientific Reports.

Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years

A. Ceci, F. Bellanti, O. Della Pasqua, 2017, British journal of clinical pharmacology.

The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.

M. Spino, J. Dunaief, J. Connelly, 2014, Investigative ophthalmology & visual science.

The Oral Iron Chelator Deferiprone Protects Against Retinal Degeneration Induced through Diverse Mechanisms.

G. Ying, M. Pajic, M. Spino, 2012, Translational vision science & technology.

Dysregulation of iron homeostasis and oxidative stress have been implicated in age-related neurodegenerative diseases including Parkinson’s and age-related macular degeneration (AMD). Because of its high metabolic rate, high content of polyunsaturated fatty acids, and presence of redox-active

J. Connor, P. Krajacic, H. Jinnah, 2015 .

Enhanced Histochemical Detection of Iron in Paraffin Sections of Mouse Central Nervous System Tissue

S. Sands, Yingsheng Wang, R. Leung-Toung, 2016, ASN neuro.

The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.

M. Spino, J. Dunaief, J. Connelly, 2014, Investigative ophthalmology & visual science.

The Oral Iron Chelator Deferiprone Protects Against Retinal Degeneration Induced through Diverse Mechanisms.

S. Grieco, J. Dunaief, J. Connelly, 2012, Translational vision science & technology.